quinolinic acid has been researched along with Epilepsy in 16 studies
Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.
pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.
quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| "There was a statistically significant decrease of CSF kynurenic acid in patients with epileptic spasms compared to OND (p<0." | 8.12 | Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of response to corticosteroids. ( Antony, J; Ardern-Holmes, S; Bandodkar, S; Dale, RC; Gill, D; Guillemin, GJ; Guller, A; Gupta, S; Han, VX; Heng, B; Innes, EA; Jones, HF; Kothur, K; Menezes, MP; Mohammad, S; Patel, S; Pires, AS; Tantsis, E; Troedson, C; Tsang, E; Webster, R; Wienholt, L; Yan, J, 2022) |
| "p." | 5.31 | Guanosine and GMP prevent seizures induced by quinolinic acid in mice. ( da Silveira Perla, A; de Faria Maraschin, J; Lara, DR; Onofre Souza, D; Schmidt, AP, 2000) |
| "There was a statistically significant decrease of CSF kynurenic acid in patients with epileptic spasms compared to OND (p<0." | 4.12 | Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of response to corticosteroids. ( Antony, J; Ardern-Holmes, S; Bandodkar, S; Dale, RC; Gill, D; Guillemin, GJ; Guller, A; Gupta, S; Han, VX; Heng, B; Innes, EA; Jones, HF; Kothur, K; Menezes, MP; Mohammad, S; Patel, S; Pires, AS; Tantsis, E; Troedson, C; Tsang, E; Webster, R; Wienholt, L; Yan, J, 2022) |
| "We had shown that production of quinolinic acid is high in the brain of epilepsy-prone El mice and that this is due to an increase in the activity of 3-hydroxyanthranilate 3,4-dioxygenase (3-HAO, EC 1." | 3.69 | Increase in the level of mRNA for 3-hydroxyanthranilate 3,4-dioxygenase in brain of epilepsy-prone El mice. ( Asai, H; Kitoh, J; Mori, H; Nakagawa, Y; Nakano, K, 1995) |
| " Several crucial questions remain to be addressed before a case can be made for a 'quinolinic acid hypothesis' of temporal lobe epilepsy." | 3.67 | Quinolinic acid: a pathogen in seizure disorders? ( French, ED; Köhler, C; Okuno, E; Schwarcz, R; Speciale, C, 1986) |
| "Quinolinic acid was not detected in the brain of patients who received antiepileptic drugs other than carbamazepine prior to surgery or in brain endothelial cultures obtained from a control patient." | 1.38 | A pro-convulsive carbamazepine metabolite: quinolinic acid in drug resistant epileptic human brain. ( Alexopoulos, AV; Ghosh, C; Gonzalez-Martinez, J; Hossain, M; Janigro, D; Marchi, N; Rasmussen, P; Yang, H, 2012) |
| "Quinolinic acid (QA) has been used as a model for experimental overstimulation of the glutamatergic system." | 1.32 | Quinolinic acid promotes seizures and decreases glutamate uptake in young rats: reversal by orally administered guanosine. ( de Oliveira, DL; Frizzo, ME; Horn, JF; Moriguchi, E; Rodrigues, JM; Souza, DO; Wofchuk, S, 2004) |
| "p." | 1.31 | Guanosine and GMP prevent seizures induced by quinolinic acid in mice. ( da Silveira Perla, A; de Faria Maraschin, J; Lara, DR; Onofre Souza, D; Schmidt, AP, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (31.25) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Yan, J | 1 |
| Kothur, K | 1 |
| Innes, EA | 1 |
| Han, VX | 1 |
| Jones, HF | 1 |
| Patel, S | 1 |
| Tsang, E | 1 |
| Webster, R | 1 |
| Gupta, S | 1 |
| Troedson, C | 1 |
| Menezes, MP | 1 |
| Antony, J | 1 |
| Ardern-Holmes, S | 1 |
| Tantsis, E | 1 |
| Mohammad, S | 1 |
| Wienholt, L | 1 |
| Pires, AS | 1 |
| Heng, B | 1 |
| Guillemin, GJ | 1 |
| Guller, A | 1 |
| Gill, D | 1 |
| Bandodkar, S | 1 |
| Dale, RC | 1 |
| Ghosh, C | 1 |
| Marchi, N | 1 |
| Hossain, M | 1 |
| Rasmussen, P | 1 |
| Alexopoulos, AV | 1 |
| Gonzalez-Martinez, J | 1 |
| Yang, H | 1 |
| Janigro, D | 1 |
| Juhász, C | 1 |
| Chugani, DC | 1 |
| Padhye, UN | 1 |
| Muzik, O | 1 |
| Shah, A | 1 |
| Asano, E | 1 |
| Mangner, TJ | 1 |
| Chakraborty, PK | 1 |
| Sood, S | 1 |
| Chugani, HT | 1 |
| de Oliveira, DL | 1 |
| Horn, JF | 1 |
| Rodrigues, JM | 1 |
| Frizzo, ME | 2 |
| Moriguchi, E | 1 |
| Souza, DO | 2 |
| Wofchuk, S | 1 |
| Rho, JM | 1 |
| Nakano, K | 2 |
| Takahashi, S | 1 |
| Mizobuchi, M | 1 |
| Kuroda, T | 1 |
| Masuda, K | 1 |
| Kitoh, J | 2 |
| Nakagawa, Y | 1 |
| Asai, H | 1 |
| Mori, H | 1 |
| Schmidt, AP | 2 |
| Lara, DR | 2 |
| de Faria Maraschin, J | 1 |
| da Silveira Perla, A | 1 |
| Onofre Souza, D | 1 |
| Stone, TW | 2 |
| Burgos, JS | 1 |
| Ramírez, G | 1 |
| Manfridi, A | 1 |
| Forloni, GL | 1 |
| Vezzani, A | 2 |
| Fodritto, F | 1 |
| De Simoni, MG | 1 |
| Ben-Ari, Y | 1 |
| Schwarcz, R | 2 |
| Connick, JH | 1 |
| Winn, P | 1 |
| Hastings, MH | 1 |
| English, M | 1 |
| Guiso, G | 1 |
| Caccia, S | 1 |
| Stasi, MA | 1 |
| Salmona, M | 1 |
| Romano, M | 1 |
| Garattini, S | 1 |
| Foster, AC | 1 |
| Speciale, C | 1 |
| Okuno, E | 1 |
| French, ED | 1 |
| Köhler, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prednisolone vs. Vigabatrin in the First-line Treatment of Infantile Spasms[NCT02299115] | Phase 3 | 0 participants (Actual) | Interventional | 2017-09-05 | Withdrawn (stopped due to Most centres are now using oral steroids as 1st line treatment so question of efficacy is no longer of high interest.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for quinolinic acid and Epilepsy
| Article | Year |
|---|---|
Basic science behind the catastrophic epilepsies.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Corticotropin-Releasing Hormone; Epilepsies | 2004 |
Kynurenic acid antagonists and kynurenine pathway inhibitors.
Topics: Brain Ischemia; Epilepsy; Excitatory Amino Acid Antagonists; Humans; Kynurenic Acid; Kynurenine; Neu | 2001 |
Endogenous excitotoxic agents.
Topics: Animals; Aspartic Acid; Cell Survival; Central Nervous System; Dementia; Epilepsy; Glutamates; Gluta | 1987 |
13 other studies available for quinolinic acid and Epilepsy
| Article | Year |
|---|---|
Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of response to corticosteroids.
Topics: 3-Hydroxyanthranilic Acid; Adrenal Cortex Hormones; Animals; Biomarkers; Chromatography, Liquid; Epi | 2022 |
A pro-convulsive carbamazepine metabolite: quinolinic acid in drug resistant epileptic human brain.
Topics: Adult; Anticonvulsants; Biotransformation; Brain Chemistry; Carbamazepine; Child; Chromatography, Hi | 2012 |
Evaluation with alpha-[11C]methyl-L-tryptophan positron emission tomography for reoperation after failed epilepsy surgery.
Topics: Adolescent; Adult; Age Factors; Carbon Radioisotopes; Child; Child, Preschool; Electroencephalograph | 2004 |
Quinolinic acid promotes seizures and decreases glutamate uptake in young rats: reversal by orally administered guanosine.
Topics: Administration, Oral; Aging; Animals; Animals, Newborn; Anticonvulsants; Brain; Disease Models, Anim | 2004 |
High levels of quinolinic acid in brain of epilepsy-prone E1 mice.
Topics: Aging; Amino Acids; Animals; Cerebral Cortex; Epilepsy; Escherichia coli; Lipopolysaccharides; Methi | 1993 |
Increase in the level of mRNA for 3-hydroxyanthranilate 3,4-dioxygenase in brain of epilepsy-prone El mice.
Topics: 3-Hydroxyanthranilate 3,4-Dioxygenase; Animals; Brain; Dioxygenases; Epilepsy; Genetic Predispositio | 1995 |
Guanosine and GMP prevent seizures induced by quinolinic acid in mice.
Topics: Animals; Anticonvulsants; Central Nervous System; Dose-Response Relationship, Drug; Drug Interaction | 2000 |
Effect of orally administered guanosine on seizures and death induced by glutamatergic agents.
Topics: Animals; Brain; Caffeine; Death; Dizocilpine Maleate; Dose-Response Relationship, Drug; Elapid Venom | 2001 |
Functional and histological consequences of quinolinic and kainic acid-induced seizures on hippocampal somatostatin neurons.
Topics: Animals; Cell Survival; Cysteamine; Electroencephalography; Epilepsy; Hippocampus; Kainic Acid; Male | 1991 |
Seizures and brain damage: are excitatory amino acids involved?
Topics: Action Potentials; Amino Acids; Animals; Brain; Epilepsy; Glutamates; Glutamic Acid; Hippocampus; Ne | 1986 |
Effect of aspartame on seizures in various models of experimental epilepsy.
Topics: Animals; Aspartame; Brain Chemistry; Dipeptides; Electroshock; Epilepsy; Male; Pentylenetetrazole; P | 1988 |
Involvement of excitatory amino acid receptors in the mechanisms underlying excitotoxic phenomena.
Topics: Action Potentials; Amino Acids, Dicarboxylic; Animals; Cell Survival; Dendrites; Epilepsy; Kynurenic | 1986 |
Quinolinic acid: a pathogen in seizure disorders?
Topics: Afferent Pathways; Animals; Brain; Brain Mapping; Cholinergic Fibers; Convulsants; Epilepsy; Kainic | 1986 |